Literature DB >> 25371442

Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis.

Chunqing Guo1, Fanlei Hu2, Huanfa Yi3, Zhitao Feng4, Changzheng Li4, Lianjie Shi2, Yingni Li2, Hongjiang Liu2, Xiaofei Yu1, Hongxia Wang1, Juan Li4, Zhanguo Li2, Xiang-Yang Wang1.   

Abstract

OBJECTIVES: Although myeloid-derived suppressor cells (MDSCs) have been linked to T cell tolerance, their role in autoimmune rheumatoid arthritis (RA) remains elusive. Here we investigate the potential association of MDSCs with the disease pathogenesis using a preclinical model of RA and specimen collected from patients with RA.
METHODS: The frequency of MDSCs in blood, lymphoid tissues, inflamed paws or synovial fluid and their association with disease severity, tissue inflammation and the levels of pathogenic T helper (Th) 17 cells were examined in arthritic mice or in patients with RA (n=35) and osteoarthritis (n=15). The MDSCs in arthritic mice were also characterised for their phenotype, inflammation status, T cell suppressive activity and their capacity of pro-Th17 cell differentiation. The involvement of MDSCs in the disease pathology and a Th17 response was examined by adoptive transfer or antibody depletion of MDSCs in arthritic mice or by coculturing mouse or human MDSCs with naïve CD4+ T cells under Th17-polarising conditions.
RESULTS: MDSCs significantly expanded in arthritic mice and in patients with RA, which correlated positively with disease severity and an inflammatory Th17 response. While displaying T cell suppressive activity, MDSCs from arthritic mice produced high levels of inflammatory cytokines (eg, interleukin (IL)-1β, TNF-α). Mouse and human MDSCs promoted Th17 cell polarisation ex vivo. Transfer of MDSCs facilitated disease progression, whereas their elimination in arthritic mice ameliorated disease symptoms concomitant with reduction of IL-17A/Th17 cells.
CONCLUSIONS: Our studies suggest that proinflammatory MDSCs with their capacity to drive Th17 cell differentiation may be a critical pathogenic factor in autoimmune arthritis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Year:  2014        PMID: 25371442      PMCID: PMC4418961          DOI: 10.1136/annrheumdis-2014-205508

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

1.  IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis.

Authors:  E Lubberts; L A Joosten; B Oppers; L van den Bersselaar; C J Coenen-de Roo; J K Kolls; P Schwarzenberger; F A van de Loo; W B van den Berg
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

Review 2.  Rheumatoid arthritis.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

3.  High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism.

Authors:  M Ziolkowska; A Koc; G Luszczykiewicz; K Ksiezopolska-Pietrzak; E Klimczak; H Chwalinska-Sadowska; W Maslinski
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

4.  Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium.

Authors:  M Chabaud; J M Durand; N Buchs; F Fossiez; G Page; L Frappart; P Miossec
Journal:  Arthritis Rheum       Date:  1999-05

5.  Collagen-induced arthritis in mice.

Authors:  Richard O Williams
Journal:  Methods Mol Med       Date:  2007

Review 6.  Evidence that cytokines play a role in rheumatoid arthritis.

Authors:  Fionula M Brennan; Iain B McInnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

7.  Blood monocytes consist of two principal subsets with distinct migratory properties.

Authors:  Frederic Geissmann; Steffen Jung; Dan R Littman
Journal:  Immunity       Date:  2003-07       Impact factor: 31.745

8.  CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis.

Authors:  Bing Zhu; Yoshio Bando; Sheng Xiao; Kaiyong Yang; Ana C Anderson; Vijay K Kuchroo; Samia J Khoury
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

9.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Authors:  Erik Lubberts; Marije I Koenders; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Christina J J Coenen-de Roo; Leo A B Joosten; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2004-02

10.  Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.

Authors:  Johanna K Morales; Maciej Kmieciak; Laura Graham; Marta Feldmesser; Harry D Bear; Masoud H Manjili
Journal:  Cancer Immunol Immunother       Date:  2008-11-01       Impact factor: 6.968

View more
  49 in total

1.  Myeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts.

Authors:  Hui Zhang; Yuefang Huang; Shuang Wang; Rong Fu; Chaohuan Guo; Hongyue Wang; Jijun Zhao; Felicia Gaskin; Jingxian Chen; Niansheng Yang; Shu Man Fu
Journal:  J Autoimmun       Date:  2015-08-28       Impact factor: 7.094

2.  Genome-epigenome interactions associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Santiago Herrera; Wilfred C de Vega; David Ashbrook; Suzanne D Vernon; Patrick O McGowan
Journal:  Epigenetics       Date:  2018-12-05       Impact factor: 4.528

Review 3.  Recent advances in myeloid-derived suppressor cell biology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani; Ammar Daoud
Journal:  Front Med       Date:  2020-09-02       Impact factor: 4.592

4.  Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation.

Authors:  Hui Zhang; Shuang Wang; Yuefang Huang; Hongyue Wang; Jijun Zhao; Felicia Gaskin; Niansheng Yang; Shu Man Fu
Journal:  Clin Immunol       Date:  2015-02-11       Impact factor: 3.969

Review 5.  Roles of estrogens on myeloid-derived suppressor cells in cancer and autoimmune diseases.

Authors:  Jing Ren; Yayi Hou; Tingting Wang
Journal:  Cell Mol Immunol       Date:  2017-12-25       Impact factor: 11.530

6.  The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.

Authors:  Chunwan Lu; Priscilla S Redd; Jeffrey R Lee; Natasha Savage; Kebin Liu
Journal:  Oncoimmunology       Date:  2016-10-20       Impact factor: 8.110

7.  Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus.

Authors:  Hao Wu; Yu Zhen; Zhanchuan Ma; Huimin Li; Jinyu Yu; Zhong-Gao Xu; Xiang-Yang Wang; Huanfa Yi; Yong-Guang Yang
Journal:  Sci Transl Med       Date:  2016-03-23       Impact factor: 17.956

8.  Monocytic MDSCs skew Th17 cells toward a pro-osteoclastogenic phenotype and potentiate bone erosion in rheumatoid arthritis.

Authors:  Shixian Chen; Chunqing Guo; Ran Wang; Zhitao Feng; Zheng Liu; Lisheng Wu; Di Zhao; Songyuan Zheng; Feilong Chen; Dingding Zhang; Juan Xu; Junqing Zhu; Xiaoguang Chen; Zhanguo Li; Christopher M Wise; Juan Li; Xiang-Yang Wang
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

Review 9.  Myeloid-derived suppressor cells coming of age.

Authors:  Filippo Veglia; Michela Perego; Dmitry Gabrilovich
Journal:  Nat Immunol       Date:  2018-01-18       Impact factor: 25.606

Review 10.  Role of Myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target.

Authors:  Ehsan Nourbakhsh; Ali Mohammadi; Mohammad Salemizadeh Parizi; Atena Mansouri; Farnoosh Ebrahimzadeh
Journal:  Inflammopharmacology       Date:  2021-07-20       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.